(Q28087109)

title

Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials (English)

1 reference

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Thomas Callender

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Kazem Rahimi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Jun Cao

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

1 reference

May 2015

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

17

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

5

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

701-710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25855678%20AND%20SRC:MED&resulttype=core&format=json

The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Antiarrhythmic drug therapy for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Incidence of and risk factors for atrial fibrillation in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Irbesartan in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Valsartan for prevention of recurrent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021

Antihypertensive treatment and risk of atrial fibrillation: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUV021